DK1251848T3 - Gyraseinhibitorer og anvendelse deraf - Google Patents

Gyraseinhibitorer og anvendelse deraf

Info

Publication number
DK1251848T3
DK1251848T3 DK01903077T DK01903077T DK1251848T3 DK 1251848 T3 DK1251848 T3 DK 1251848T3 DK 01903077 T DK01903077 T DK 01903077T DK 01903077 T DK01903077 T DK 01903077T DK 1251848 T3 DK1251848 T3 DK 1251848T3
Authority
DK
Denmark
Prior art keywords
gyrase inhibitors
gyrase
inhibitors
Prior art date
Application number
DK01903077T
Other languages
English (en)
Inventor
Steven Ronkin
Paul Charifson
Dean Stamos
Michael Badia
Anne-Laure Grillot
Martin Trudeau
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of DK1251848T3 publication Critical patent/DK1251848T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK01903077T 2000-01-18 2001-01-16 Gyraseinhibitorer og anvendelse deraf DK1251848T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17667100P 2000-01-18 2000-01-18
US25433100P 2000-12-08 2000-12-08
EP01903077A EP1251848B1 (en) 2000-01-18 2001-01-16 Gyrase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
DK1251848T3 true DK1251848T3 (da) 2004-10-18

Family

ID=26872470

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01903077T DK1251848T3 (da) 2000-01-18 2001-01-16 Gyraseinhibitorer og anvendelse deraf

Country Status (23)

Country Link
US (2) US6608087B1 (da)
EP (1) EP1251848B1 (da)
JP (1) JP2003520233A (da)
CN (1) CN1230166C (da)
AR (1) AR027518A1 (da)
AT (1) ATE269701T1 (da)
AU (1) AU782883B2 (da)
BR (1) BR0107713A (da)
CA (1) CA2397686A1 (da)
CO (1) CO5261612A1 (da)
DE (1) DE60103974T2 (da)
DK (1) DK1251848T3 (da)
EA (1) EA005680B1 (da)
ES (1) ES2222336T3 (da)
HK (1) HK1053984B (da)
MX (1) MXPA02007134A (da)
MY (1) MY133572A (da)
NZ (1) NZ520628A (da)
PT (1) PT1251848E (da)
SI (1) SI1251848T1 (da)
TR (1) TR200401735T4 (da)
TW (1) TWI287449B (da)
WO (1) WO2001052845A1 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002256418A1 (en) * 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
DE60211348T2 (de) * 2001-08-13 2007-02-08 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
CA2587224A1 (en) * 2004-11-19 2006-05-26 Plant Bioscience Limited Microcin b17 analogs and methods for their preparation and use
BRPI0607756A2 (pt) 2005-02-18 2010-05-18 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibição de dna girase bacteriana e/ou topoisomerase iv em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para preparar compostos ou sais farmaceuticamente aceitáveis dos mesmos
CA2642754A1 (en) * 2006-02-13 2007-08-23 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
US9149262B2 (en) 2006-06-21 2015-10-06 Cook Biotech Incorporated Fistula grafts and related methods and systems useful for treating gastrointestinal fistulae
WO2008019292A2 (en) * 2006-08-04 2008-02-14 Trustees Of Boston University Compositions and methods for potentiating antibiotic activity
TW200906412A (en) * 2007-06-12 2009-02-16 Astrazeneca Ab Piperidine compounds and uses thereof
CN101918389A (zh) * 2007-11-02 2010-12-15 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US8865732B2 (en) * 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
AU2009227013B2 (en) * 2008-03-21 2013-01-10 Novartis Ag Novel heterocyclic compounds and uses therof
KR20100122513A (ko) * 2008-07-17 2010-11-22 아사히 가세이 파마 가부시키가이샤 질소 함유 복소환 화합물
CA2736955C (en) * 2008-09-22 2016-02-16 Gregory W. Endres Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
US8071605B2 (en) 2008-12-12 2011-12-06 Astrazeneca Ab Piperidine compounds for use in the treatment of bacterial infections
TW201026694A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Compound 468
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2750935A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
TW201102065A (en) 2009-05-29 2011-01-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
WO2011024004A1 (en) 2009-08-26 2011-03-03 Astrazeneca Ab Heterocyclic urea derivatives useful for treatment of bacterial infection
SG181643A1 (en) * 2009-12-17 2012-07-30 Merck Patent Gmbh Inhibitors of sphingosine kinase
JP2013536193A (ja) 2010-08-11 2013-09-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリール類およびその使用
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012051410A2 (en) 2010-10-13 2012-04-19 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102911173A (zh) * 2012-11-08 2013-02-06 苏州施亚生物科技有限公司 5,6,7,8-四氢-2H-吡啶并[4,3-c]哒嗪-3-酮的合成方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
KR20160115986A (ko) 2014-02-03 2016-10-06 스페로 자이레이스, 인크 폴리믹신을 포함하는 항균성 조합
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3604281A4 (en) 2017-03-24 2020-08-19 Taisho Pharmaceutical Co., Ltd. 2 (1H) -CHINOLINONE DERIVATIVE
US11666555B2 (en) 2017-05-17 2023-06-06 Drexel University RelA inhibitors for biofilm disruption
WO2020048949A1 (en) 2018-09-03 2020-03-12 Univerza V Ljubljani New class of dna gyrase and/or topoisomerase iv inhibitors with activity against gram-positive and gram-negative bacteria
EP4263503A1 (en) 2020-12-17 2023-10-25 Univerza V Ljubljani New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925659A (en) * 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
DK0913151T3 (da) * 1996-05-09 2002-10-14 Sankyo Co Anti-helicobacter Pylori-præparater indeholdende 1-methylcarbapenemderivater som den aktive bestanddel

Also Published As

Publication number Publication date
MXPA02007134A (es) 2003-03-27
AU3094001A (en) 2001-07-31
SI1251848T1 (en) 2004-12-31
HK1053984A1 (en) 2003-11-14
NZ520628A (en) 2004-05-28
US6608087B1 (en) 2003-08-19
AU782883B2 (en) 2005-09-08
ATE269701T1 (de) 2004-07-15
US6930116B2 (en) 2005-08-16
PT1251848E (pt) 2004-10-29
US20040024030A1 (en) 2004-02-05
HK1053984B (zh) 2006-07-28
CA2397686A1 (en) 2001-07-26
CN1400898A (zh) 2003-03-05
EA005680B1 (ru) 2005-04-28
WO2001052845A1 (en) 2001-07-26
TR200401735T4 (tr) 2004-08-23
EP1251848B1 (en) 2004-06-23
DE60103974T2 (de) 2005-06-30
ES2222336T3 (es) 2005-02-01
EP1251848A1 (en) 2002-10-30
DE60103974D1 (de) 2004-07-29
EA200200769A1 (ru) 2002-12-26
MY133572A (en) 2007-11-30
TWI287449B (en) 2007-10-01
BR0107713A (pt) 2002-11-19
AR027518A1 (es) 2003-04-02
CN1230166C (zh) 2005-12-07
CO5261612A1 (es) 2003-03-31
JP2003520233A (ja) 2003-07-02

Similar Documents

Publication Publication Date Title
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
NO20032668D0 (no) Gyraseinhibitorer og anvendelser derav
NO20020343D0 (no) Kaspase-inhibitorer og anvendelse derav
NO20022656D0 (no) Caspaseinhibitorer og anvendelse derav
DK1268425T3 (da) Carbamatcaspaseinhibitorer og anvendelse deraf
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
NO20042229L (no) Type 4-fosfodiestemseinhibitorer og anvendelse derav
NO20024355L (no) Nukleosidforbindelser og anvendelser derav
NO20014823L (no) Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
NO20024709D0 (no) Borefluider og anvendelse derav
IS6822A (is) Imidazól- og bezimidazól kaspasatálmar og notkun þeirra
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
DK1322597T3 (da) Fremgangsmåde og intermediære
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20030156L (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
NO20055668D0 (no) Beta-amyloidinhibitorer og anvendelse derav
PT1339695E (pt) Inibidores da farnesiltransferase
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
NO20032821D0 (no) Sea-trosy og beslektede fremgangsmåter
NO20026065D0 (no) Prosesser for måling av dinofysistoksin og av yessotoksin
NO20025135L (no) Antihypertensive midler og anvendelse